Mitokinin is operates in the healthcare industry focusing on biotechnology business.

Mitokinin has advanced small molecule therapeutics that specifically increase the activity of active-form PINK1. Importantly, Mitokinin’s compounds do not interfere with the endogenous regulation of PINK1.

PINK1 is a master regulator of mitochondrial quality control. Mutations in PINK1 give rise to familial forms of Parkinson’s disease. Increased PINK1 activity rescues pathologies associated with neurodegenerative disease.

Mitokinin has an accomplished team of neuroscientists, chemists, pharmacologists, and administrative professionals all focused on our mission: delivering disease-modifying therapies for neurodegenerative disease.

Biotechnology

Health Care

Life Sciences

Mitokinin

Daniel De Roulet

Dara Ditsworth

Randall Chin

Rishi Rakhit

Nicholas Hertz

The Research and Development Team at Mitokinin is dedicated to advancing the company’s innovative therapeutics targeting PINK1 activity. Comprising neuroscientists, chemists, and pharmacologists, the team conducts extensive research to develop and optimize small molecule drugs, ensuring they enhance mitochondrial quality control without disrupting existing PINK1 regulation. Their efforts are crucial in the pursuit of effective, disease-modifying therapies for neurodegenerative diseases such as Parkinson's.

Research and Development Team

Scientific Advisory Team

Leadership Team

Research and Development Team

About

Team members

Other teams at Mitokinin

Scientific Advisory Team

Leadership Team